Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 9, 2007

Genedata Expands Collaboration with HepatoSys Systems Biology Network

  • Genedata extended its collaboration with the HepatoSys research network by three years. HepatoSys, an interdisciplinary initiative funded in 2003 by several German research centers, aims to understand the physiology and pathophysiology of the human liver cell using a systems biology approach.

    In the first funding period of HepatoSys, Genedata was tasked to develop and establish a computational platform to serve as the consortium's central data storage and analysis infrastructure. The platform—built on Genedata's Phylosopher® and Expressionist®—was successfully deployed and is now being used by the consortium.

    The centralized data storage infrastructure enables an integrative approach to the interpretation of systems biology modeling results in the context of experimental findings, including high-throughput transcriptomics, proteomics, and metabolomics data.

    Taking the collaboration to the next level, Genedata will now work on data analysis projects to interpret the huge amounts of molecular profiling data generated within the HepatoSys consortium.

    "After having built successfully on Genedata's track record in developing our scientific computing infrastructure, we see a tremendous opportunity in bringing together our academic expertise with Genedata's know-how to transfer systems biology applications to the pharmaceutical industry," remarks Jens Timmer, scientific spokesman for HepatoSys.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »